JP2013533846A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013533846A5 JP2013533846A5 JP2013503921A JP2013503921A JP2013533846A5 JP 2013533846 A5 JP2013533846 A5 JP 2013533846A5 JP 2013503921 A JP2013503921 A JP 2013503921A JP 2013503921 A JP2013503921 A JP 2013503921A JP 2013533846 A5 JP2013533846 A5 JP 2013533846A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cyano
- alkenyl
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000011664 signaling Effects 0.000 claims description 7
- 102000005962 receptors Human genes 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 230000036755 cellular response Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 125000004093 cyano group Chemical group *C#N 0.000 claims 20
- 125000003342 alkenyl group Chemical group 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 11
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 11
- 125000001475 halogen functional group Chemical group 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 7
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- -1 carboxy, hydroxy Chemical group 0.000 claims 2
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 description 4
- 0 **c1c(*)c(*)c(*)c(C=NNC(COc2c(*)c(*)c(*)c(*)c2*)=O)c1O* Chemical compound **c1c(*)c(*)c(*)c(C=NNC(COc2c(*)c(*)c(*)c(*)c2*)=O)c1O* 0.000 description 2
- 102000016979 Other receptors Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32132410P | 2010-04-06 | 2010-04-06 | |
| US61/321,324 | 2010-04-06 | ||
| US32238310P | 2010-04-09 | 2010-04-09 | |
| US61/322,383 | 2010-04-09 | ||
| US32568210P | 2010-04-19 | 2010-04-19 | |
| US61/325,682 | 2010-04-19 | ||
| PCT/US2011/031448 WO2011127192A2 (en) | 2010-04-06 | 2011-04-06 | Antimetastatic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013533846A JP2013533846A (ja) | 2013-08-29 |
| JP2013533846A5 true JP2013533846A5 (https=) | 2014-05-22 |
Family
ID=44763529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013503921A Pending JP2013533846A (ja) | 2010-04-06 | 2011-04-06 | 抗転移化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8481553B2 (https=) |
| EP (1) | EP2555766A4 (https=) |
| JP (1) | JP2013533846A (https=) |
| AU (1) | AU2011237642B2 (https=) |
| CA (1) | CA2794112A1 (https=) |
| WO (1) | WO2011127192A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012083866A1 (en) * | 2010-12-22 | 2012-06-28 | The Hong Kong Polytechnic University | Quinoline derivatives as anti-cancer agents |
| WO2012097196A1 (en) * | 2011-01-12 | 2012-07-19 | Acea Biosciences Inc. | Pyrazolopyrimidine derivatives and uses as anticancer agents |
| JP5955531B2 (ja) * | 2011-11-07 | 2016-07-20 | 千葉県 | 抗癌剤 |
| WO2014009891A1 (en) * | 2012-07-11 | 2014-01-16 | Piramal Enterprises Limited | Heterocyclic compounds for use in the treatment of cancers |
| AU2014254078A1 (en) | 2013-04-19 | 2015-10-15 | Bioventures, Llc | Combretastatin analogs |
| WO2015153635A1 (en) | 2014-03-31 | 2015-10-08 | Board Of Trustees Of The University Of Arkansas | Disubstituted triazole analogs |
| WO2016040951A1 (en) * | 2014-09-12 | 2016-03-17 | Vanderbilt University | Compounds and methods for inhibition of hedgehog signaling and phosphodiesterase |
| US10329304B2 (en) * | 2014-09-12 | 2019-06-25 | Vanderbilt University | Compounds and methods for inhibition of hedgehog signaling and phosphodiesterase |
| EP3303346B1 (en) | 2015-05-28 | 2020-09-16 | The Regents of the University of California | Tubulin-binding compounds, compositions and uses related thereto |
| WO2018102766A2 (en) * | 2016-12-01 | 2018-06-07 | Oregon State University | Small molecule bcl-2 functional converters as cancer therapeutics |
| WO2018144910A1 (en) | 2017-02-02 | 2018-08-09 | Bioventures, Llc | Methods of protecting against neurodegeneration |
| CN106905347B (zh) * | 2017-04-18 | 2019-04-16 | 四川大学 | Brd4抑制剂及其在肿瘤治疗药物中的应用 |
| KR102131331B1 (ko) * | 2018-09-19 | 2020-07-07 | 연세대학교 산학협력단 | 항암용 신규 약학 조성물 및 ano1 활성억제제 |
| CN110590806B (zh) * | 2019-09-27 | 2021-10-29 | 深圳大学 | 含噻吩并[2,3-d]嘧啶-2-基的查耳酮类似物及其制备方法和用途 |
| CN111494381B (zh) * | 2020-04-30 | 2023-07-28 | 南方医科大学 | 烯基喹啉化合物在制备抗肿瘤药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW349948B (en) | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
| US20030008369A1 (en) * | 1999-03-03 | 2003-01-09 | Board Of Regents, The University Of Texas System | Genetic and epigenetic manipulation of ABC transporters and ecto-phosphatases |
| US20030028018A1 (en) | 2000-09-11 | 2003-02-06 | Chiron Coporation | Quinolinone derivatives |
| MXPA06000276A (es) * | 2003-07-02 | 2006-04-07 | Sugen Inc | Indolinona hidrazidas como inhibidores de c-met. |
| DE10346913A1 (de) * | 2003-10-09 | 2005-05-04 | Merck Patent Gmbh | Acylhydrazonderivate |
| DE10348044A1 (de) * | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| CA2556025A1 (en) * | 2004-02-23 | 2005-09-09 | Sugen, Inc. | Method of treating abnormal cell growth using c-met and m-tor inhibitors |
| WO2006093518A2 (en) * | 2004-06-25 | 2006-09-08 | Apath, Llc | Thienyl compounds for treating virus-related conditions |
| WO2006044826A2 (en) * | 2004-10-20 | 2006-04-27 | Compass Pharmaceuticals Llc | Thiophens and their use as anti-tumor agents |
| WO2008021250A2 (en) * | 2006-08-10 | 2008-02-21 | Fred Hutchinson Cancer Research Center | Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins |
| WO2009086303A2 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2009155362A1 (en) * | 2008-06-19 | 2009-12-23 | Ligand Pharmaceuticals Inc. | Small molecule hematopoietic growth factor mimetic compounds and their uses |
| US20130158035A1 (en) | 2010-08-24 | 2013-06-20 | Brigham Young University | Antimetastatic compounds |
-
2011
- 2011-04-06 WO PCT/US2011/031448 patent/WO2011127192A2/en not_active Ceased
- 2011-04-06 US US13/639,397 patent/US8481553B2/en not_active Expired - Fee Related
- 2011-04-06 EP EP11766671.9A patent/EP2555766A4/en not_active Withdrawn
- 2011-04-06 AU AU2011237642A patent/AU2011237642B2/en not_active Ceased
- 2011-04-06 JP JP2013503921A patent/JP2013533846A/ja active Pending
- 2011-04-06 CA CA2794112A patent/CA2794112A1/en not_active Abandoned
-
2013
- 2013-03-18 US US13/846,421 patent/US20130225610A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013533846A5 (https=) | ||
| JP2016503793A5 (https=) | ||
| JP2008523153A5 (https=) | ||
| JP2013517798A5 (https=) | ||
| JP2020500916A5 (https=) | ||
| JP2016195616A5 (https=) | ||
| JP2016040288A5 (https=) | ||
| JP2014519662A5 (https=) | ||
| CL2012001841A1 (es) | Polimorfo cristalino de la forma a de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetato de sodio; método de preparación; composición farmacéutica; y su uso para el tratamiento o prevención de hiperuricemia o una enfermedad causada por niveles elevados de ácido úrico. | |
| JP2022510882A5 (https=) | ||
| EA201400056A1 (ru) | Вещества, связывающие ядерные рецепторы | |
| JO3501B1 (ar) | مشتقات 5-{(بيبرازين - 1-يل)-3-أوكسو - بروبيل}- إيميدازوليدين-2، 4 - دايون كمثبطات ل adamts لمعالجة هشاشة العظام) | |
| JO3407B1 (ar) | مركبات رباعي هيدرو بيرازولو بيريميدين | |
| JP2013514367A5 (https=) | ||
| JP2016523701A5 (https=) | ||
| JP2014500861A5 (https=) | ||
| JP2008540554A5 (https=) | ||
| JP2014505107A5 (https=) | ||
| JP2012513416A5 (https=) | ||
| JP2014532727A5 (https=) | ||
| JP2016513687A5 (https=) | ||
| JP2014533241A5 (https=) | ||
| JP2018521056A5 (https=) | ||
| CN113939514A (zh) | 吡咯并嘧啶类化合物及其应用 | |
| JP2015521156A5 (https=) |